Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Efalizumab for Treatment of Patients With Moderate to Severe Psoriasis

This study has been completed.
Sponsor:
Information provided by:
Merck KGaA
ClinicalTrials.gov Identifier:
NCT00442650
First received: February 28, 2007
Last updated: November 18, 2016
Last verified: March 2009
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: December 2005
  Primary Completion Date: December 2005 (Final data collection date for primary outcome measure)
Publications: